Daxor (NASDAQ:DXR) Announces Earnings Results

Daxor (NASDAQ:DXR) released its earnings results on Monday. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07), FiscalAI reports. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $2.80 million.

Daxor Stock Performance

Shares of DXR traded down $0.30 during mid-day trading on Monday, hitting $9.90. The stock had a trading volume of 872 shares, compared to its average volume of 6,900. Daxor has a 52 week low of $8.56 and a 52 week high of $14.76. The business has a fifty day moving average price of $10.38 and a 200-day moving average price of $10.56.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “hold (c)” rating on shares of Daxor in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy”.

Institutional Investors Weigh In On Daxor

An institutional investor recently bought a new position in Daxor stock. Osaic Holdings Inc. acquired a new stake in Daxor Corporation (NASDAQ:DXR) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned 0.18% of Daxor as of its most recent filing with the SEC. Institutional investors and hedge funds own 1.34% of the company’s stock.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.